QUOTE AND NEWS
Reuters  Jul 31  Comment 
Private equity firm Advent International is in advanced talks to acquire inVentiv Group Holdings in a deal that could value the U.S. pharmaceutical research firm at close to $4 billion,...
Reuters  Jul 27  Comment 
Buyout firms Advent International and CVC Capital Partners have made offers to acquire inVentiv Group Holdings, a pharmaceutical research firm seeking to go public at a valuation of over...
FierceBiotech  Mar 4  Comment 
In keeping with a trend among pharma outsourcers, inVentiv Health is considering going public, according to Reuters, lining up underwriters for a return to Wall Street that could raise $500 million.
Reuters  Mar 3  Comment 
InVentiv Health Inc, a U.S. provider of consulting and research services to biopharmaceutical companies, has hired underwriters for an initial public offering that could raise around $500...
TheStreet.com  Sep 1  Comment 
NEW YORK (TheStreet) -- Shares of Xerox were falling 2.1% to $9.96 Tuesday after the IT company announced that it acquired inVentiv Patient Access Solution (iPAS), a subsidiary of inVentiv Health. Xerox said the acquisition will expand its...
StreetInsider.com  Oct 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/inVentiv+Health+to+Replace+eTMF+CMS+with+Veeva+Systems%27+%28VEEV%29+Vault+eTMF/9926410.html for the full story.
DailyFinance  Aug 21  Comment 
NEW YORK, NY -- (Marketwired) -- 08/21/14 -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels...
DailyFinance  Apr 14  Comment 
NEW YORK, NY -- (Marketwired) -- 04/14/14 -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found...
FierceBiotech  Aug 6  Comment 
The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki